Core Viewpoint - Alumis Inc (NASDAQ:ALMS) is experiencing significant stock price growth following successful trial results for its psoriasis drug, envudeucitinib, positioning the company as a strong competitor in the biopharmaceutical market for autoimmune diseases [2][5]. Group 1: Stock Performance - The stock price of ALMS surged 107.9% to $17.28 after the successful phase three trial results of envudeucitinib [2][5]. - ALMS is on track to break a seven-day losing streak, with a year-over-year increase of approximately 108% [3]. - The stock price rose by $8.64, with a trading range from $16.40 to $22.30, marking its highest price over the past year [3]. Group 2: Market Capitalization and Trading Activity - The market capitalization of ALMS is approximately $1.77 billion [4][5]. - The trading volume for ALMS reached 49.14 million shares, with significant activity in the options market, including 3,492 calls and 5,948 puts traded, marking a volume 39 times higher than the stock's average daily options activity [4][5]. Group 3: Analyst Ratings - Wells Fargo maintained an "Overweight" rating for ALMS, raising the price target from $17 to $39 [1][5].

Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company is leveraging a proprietary data analytics platform and precision approach to develop its pipeline of therapies [5] Public Offering Announcement - Alumis announced plans to commence an underwritten public offering of $175.0 million of its common stock, with an additional option for underwriters to purchase up to $26.25 million of shares [1] - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1] Management of the Offering - Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering [2] Regulatory Compliance - The offering is being made pursuant to a shelf registration statement on Form S-3, which was previously filed and declared effective by the SEC on August 19, 2025 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]

Core Insights - Alumis Inc (NASDAQ:ALMS) shares surged by 107.9% to $17.28 after the company announced that its plaque psoriasis drug, envudeucitinib, successfully met all primary and secondary endpoints in both phase three trials [1] Group 1: Stock Performance - ALMS has reached record highs today, aiming to end a seven-day losing streak and potentially achieving its best day on record, with a year-over-year increase of approximately 100% [2] - The stock's options market is experiencing significant activity, with 3,492 calls and 5,948 puts traded, which is 39 times the average daily options volume [3] Group 2: Market Dynamics - The stock has been placed on the short sell restricted (SSR) list due to its volatility, with short interest accounting for 6.2% of the available float, equating to four days of potential buying power [4]

Core Insights - Alumis Inc. (NASDAQ:ALMS) stock is experiencing a significant increase, trading at a new 52-week high of $17.91, up 115.58% [8] - The company released positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials for envudeucitinib, a treatment for moderate-to-severe plaque psoriasis [1][3] Clinical Trial Results - Envudeucitinib met all primary and secondary endpoints with high statistical significance in both ONWARD1 and ONWARD2 trials [3] - On average, 74% of patients achieved a Psoriasis Area and Severity Index (PASI) 75 response, and 59% achieved a static Physician's Global Assessment (sPGA) 0/1 at Week 16 [4] - At Week 24, approximately 65% of patients achieved PASI 90, and over 40% achieved PASI 100 across both trials [4] - Rapid responses were noted, with significant separation from placebo on PASI 90 as early as Week 4 [5] Comparative Efficacy - Envudeucitinib demonstrated superior skin clearance compared to Amgen Inc.'s Otezla (apremilast) on all PASI endpoints at Week 24 [5] - Consistent and clinically meaningful improvements were observed in patient-reported outcomes related to itch and quality of life [5] Safety Profile - Treatment with envudeucitinib was generally well tolerated through Week 24, with a safety profile consistent with Alumis' Phase 2 program [6] Future Developments - Alumis plans to present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting and intends to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2026 [7] - Topline data from the LUMUS Phase 2b trial of envudeucitinib in systemic lupus erythematosus (SLE) is expected in the third quarter of 2026 [7]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 100 points on Tuesday [1] - Microchip Technology Inc's shares rose significantly after the company revised its fiscal third-quarter revenue expectations upward [1] Group 2: Microchip Technology Inc - Microchip now anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, surpassing its previous guidance range of $1.109 billion to $1.149 billion [2] - The stock price of Microchip Technology increased by 8.1%, reaching $72.47 on Tuesday following the announcement [2] Group 3: Other Notable Stock Movements - Alumis Inc saw a remarkable 129% increase in its stock price to $19.04 after positive trial results for envudeucitinib [3] - Aeva Technologies Inc's stock rose by 31.5% to $17.21 due to its technology being selected for NVIDIA's autonomous vehicle platform [3] - Terrestrial Energy Inc's shares increased by 26.9% to $8.87 after securing an agreement with the U.S. Department of Energy [3] - Bright Minds Biosciences Inc gained 25% to $100.00 following successful Phase 2 trial results [3] - OneStream Inc's stock rose by 25.1% to $23.00 amid reports of a potential buyout [3] - Other companies such as SanDisk Corp, Beam Therapeutics Inc, and Albemarle Corp also recorded significant stock price increases [3]

在ONWARD1和ONWARD2中，Envudeucitinib以高统计学显著性达到了所有主要和次要终点。在这些试 验中，Envudeucitinib在第16周的银屑病面积和严重程度指数(PASI)75和静态医生整体评估(sPGA)0/1共 同主要终点上，相对于安慰剂表现出更优的皮肤清除效果(p<0.0001)。在ONWARD1和ONWARD2中平 均来看，74%的患者达到PASI75，59%的患者达到sPGA0/1，随着时间推移反应加深。此外，两个试验 之间共同主要终点的安慰剂校正响应率保持一致。 周二，Alumis(ALMS.US)开盘飙升超154%，创历史新高，报20.60美元。消息面上，该公司宣布了其 envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。Envudeucitinib是一种下一代高度 选择性的口服酪氨酸激酶2(TYK2)抑制剂，针对中度至重度斑块状银屑病患者。 ...

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite gaining over 50 points, while the Dow decreased by 0.03% to 48,962.01 and the S&P 500 rose by 0.14% to 6,911.52 [1] - Energy shares increased by 2.9%, while utilities stocks fell by 2.2% [1] Company Earnings - AngioDynamics, Inc. reported better-than-expected second-quarter results with an adjusted EPS of $0.00, surpassing market estimates of a loss of $0.10 per share. Sales reached $79.433 million, exceeding expectations of $76.300 million [2] Commodity Prices - Oil prices rose by 0.5% to $58.58, gold increased by 0.6% to $4,477.40, silver gained 2.4% to $78.505, and copper rose by 1.4% to $6.0565 [5] European Market Performance - European shares were mostly higher, with the eurozone's STOXX 600 gaining 0.3%, Spain's IBEX 35 Index rising 0.5%, London's FTSE 100 increasing by 1%, Germany's DAX gaining 0.4%, and France's CAC 40 slipping by 0.3% [6] Asian Market Performance - Asian markets closed mostly higher, with Japan's Nikkei 225 up 1.32%, Hong Kong's Hang Seng Index up 1.38%, China's Shanghai Composite surging 1.50%, while India's BSE Sensex fell by 0.44% [7] Notable Stock Movements - Alumis Inc. shares surged 148% to $20.54 following positive Phase 3 trial results for envudeucitinib in psoriasis [8] - Envirotech Vehicles, Inc. shares rose 73% to $0.6699 after announcing a merger transaction [8] - Cyclerion Therapeutics Inc. shares increased by 54% to $2.13 due to an expanded collaboration with Medsteer [8] - Instil Bio Inc. shares dropped 53% to $5.78 after discontinuing clinical development of AXN-2510 [8] - MOBIX LABS, INC. shares fell 45% to $0.18 following a $6.0 million stock offering [8] - BitVentures Ltd – ADR shares decreased by 23% to $11.40 [8] Economic Indicator - The Logistics Manager's Index declined for the second consecutive month to 54.2 in December, down from 55.7 in the previous two months [9]

在ONWARD1和ONWARD2中，Envudeucitinib以高统计学显著性达到了所有主要和次要终点。在这些试 验中，Envudeucitinib在第16周的银屑病面积和严重程度指数(PASI)75和静态医生整体评估(sPGA)0/1共 同主要终点上，相对于安慰剂表现出更优的皮肤清除效果(p < 0.0001)。在ONWARD1和ONWARD2中平 均来看，74%的患者达到PASI 75，59%的患者达到sPGA 0/1，随着时间推移反应加深。此外，两个试验 之间共同主要终点的安慰剂校正响应率保持一致。 智通财经APP获悉，周二，Alumis(ALMS.US)开盘飙升超154%，创历史新高，报20.60美元。消息面 上，该公司宣布了其envudeucitinib三期ONWARD1和ONWARD2临床试验的积极顶线结果。 Envudeucitinib是一种下一代高度选择性的口服酪氨酸激酶2(TYK2)抑制剂，针对中度至重度斑块状银屑 病患者。 ...

Summary of Alumis Conference Call Company Overview - **Company**: Alumis - **Lead Candidate**: Nvudusitinib, a next-generation TYK2 inhibitor - **Focus**: Treatment of moderate to severe plaque psoriasis and potential applications in other immune-mediated diseases Key Points from the Call Clinical Results - **Phase 3 Results**: Positive outcomes for Nvudusitinib, exceeding Phase 2 results with statistically significant efficacy on primary and secondary endpoints [4][5] - **Efficacy Metrics**: - 74% of patients achieved PASI 75 and 59% achieved sPGA 0/1 at week 16 [12] - Approximately 65% achieved PASI 90 and over 40% achieved PASI 100 at week 24 [12] - **Safety Profile**: Favorable safety and tolerability consistent with Phase 2 data, with most adverse events being mild to moderate [13] Market Opportunity - **Psoriasis Market**: Expected to reach $40 billion by 2030, with many patients currently underserved [6] - **Treatment Landscape**: Less than 20% of patients receive systemic treatment, and only 8% are treated with high-efficacy drugs [21] - **Patient Preferences**: 75% of patients prefer oral therapies over biologics, highlighting the demand for convenient treatment options [24] Future Developments - **NDA Filing**: Anticipated in the second half of 2026, pending data from the randomized withdrawal portion of the Phase 3 trial [37] - **Additional Trials**: Plans for a pivotal Phase 2b trial in systemic lupus erythematosus (SLE) with top-line data expected in Q3 2026 [6][28] - **Pipeline Expansion**: Development of A005, a CNS-penetrant TYK2 inhibitor, with a Phase 2 trial in multiple sclerosis planned for the first half of the year [27] Competitive Landscape - **Comparison with Competitors**: Nvudusitinib shows competitive efficacy compared to other oral therapies, including Icotrokinra and Apremilast [32][50] - **Mechanism of Action**: TYK2 inhibition may provide additional benefits beyond IL-23 and IL-17 pathways, particularly in itch reduction [51] Strategic Insights - **Market Positioning**: Alumis aims to position Nvudusitinib as a leading oral therapy for psoriasis, addressing significant unmet needs in the market [20][25] - **Partnership Considerations**: The company is evaluating strategic partnerships to maximize the asset's value, particularly in light of its broad potential across multiple indications [54] Additional Considerations - **Patient-Reported Outcomes**: Improvements in quality of life and itch were noted, which are critical factors for patient satisfaction [5][19] - **Regulatory Strategy**: Ongoing discussions with the FDA regarding the NDA filing and statistical analysis plans [38] Conclusion - **Outlook for 2026**: Alumis anticipates significant value inflection with the advancement of Nvudusitinib and its broader pipeline, aiming to address the substantial unmet needs in the treatment of psoriasis and other immune-mediated diseases [77]

Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast – January 6, 2026 1 Forward-Looking Statements This presentation contains forward looking statements within the meaning of federal securities laws, including the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of management of Alumis Inc. ("Alumis") in light of historical results and trends, current conditions and p ...